191361 Update from the Industry

Monday, October 27, 2008: 11:50 AM

Alan Goldhammer, PhD , Deputy V.P. for Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, Washington, DC
The presentation will present the pharmaceutical industry's view of the FDAA, and will provide an update on recent drug safety initiatives. The presentation will discuss the major role of the industry in identifying adverse drug events and risks, as well as the adequacy of safeguards to prevent bias in the reporting of these effects.

Learning Objectives:
1. Recognize the efforts of the pharmaceutical industry in assuring the safety of its products. 2. Evaluate the potential conflicts that exist in industry’s role in identifying and reporting adverse drug events.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: tba
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Drug Safety and FDA Reform: Are we better off now?
See more of: Medical Care